BerGenBio ASA
BRRGF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $0 | $1 |
| % Growth | 139.5% | -9% | -49.7% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $0 | $0 | $1 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $88 | $108 | $8 | $13 |
| G&A Expenses | $0 | $0 | $0 | $13 |
| SG&A Expenses | $0 | $0 | $105 | $13 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $64 | $84 | $298 | $290 |
| Operating Expenses | $152 | $192 | $306 | $315 |
| Operating Income | -$151 | -$192 | -$306 | -$314 |
| % Margin | -17,834.2% | -54,186.2% | -78,569.4% | -40,628.4% |
| Other Income/Exp. Net | $12 | $1 | $4 | $5 |
| Pre-Tax Income | -$139 | -$190 | -$302 | -$309 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$139 | -$190 | -$299 | -$309 |
| % Margin | -16,424.8% | -53,785.6% | -76,763.2% | -39,976.4% |
| EPS | -11.65 | -19.95 | -38.65 | -40.36 |
| % Growth | 41.6% | 48.4% | 4.2% | – |
| EPS Diluted | -11.65 | -19.95 | -38.65 | -40.36 |
| Weighted Avg Shares Out | 12 | 10 | 8 | 8 |
| Weighted Avg Shares Out Dil | 12 | 10 | 8 | 8 |
| Supplemental Information | – | – | – | – |
| Interest Income | $17 | $3 | $3 | $3 |
| Interest Expense | $5 | $1 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $1 | $1 |
| EBITDA | -$134 | -$190 | -$301 | -$308 |
| % Margin | -15,816.7% | -53,559.3% | -77,356.8% | -39,793.2% |